|
2023
|
Invention
|
Fused heteroaromatic pyrrolidinones.
Disclosed are compounds of Formula 1,
Disclosed are compo... |
|
2021
|
Invention
|
Interleukin 4 (il4)-induced gene 1 inhibitors and methods of use thereof. The invention relates t... |
|
|
Invention
|
Methods of administering glutaminase inhibitors. In some aspects, the invention relates to a meth... |
|
|
G/S
|
Pharmaceutical preparations for human use, except cancer pharmaceuticals.
Pharmaceutical preparat... |
|
|
Invention
|
Combination therapy with glutaminase inhibitors and immuno-oncology agents.
The invention relate... |
|
|
G/S
|
House mark for pharmaceutical preparations for human use |
|
2020
|
Invention
|
Compositions and methods for inhibiting arginase activity.
The invention relates to methods of t... |
|
|
Invention
|
Compositions and methods for inhibiting arginase activity.
The invention relates to a novel clas... |
|
|
Invention
|
Heterocyclic glutaminase inhibitors.
The invention relates to novel heterocyclic compounds and p... |
|
|
Invention
|
Ectonucleotidase inhibitors and methods of use thereof. The invention relates to novel heterocycl... |
|
2019
|
Invention
|
Heterocyclic inhibitors of glutaminase.
The invention relates to novel heterocyclic compounds an... |
|
|
Invention
|
Compositions and methods for inhibiting arginase activity. The invention relates to methods of tr... |
|
|
Invention
|
Crystal forms of glutaminase inhibitors. The invention relates to crystalline salts of a compound... |
|
|
Invention
|
Combination therapy with glutaminase inhibitors and immuno-oncology agents. The invention relates... |
|
|
G/S
|
Pharmaceuticals. |
|
2018
|
Invention
|
Conjoint therapy with glutaminase inhibitors.
The invention relates to methods of treating cance... |
|
|
Invention
|
Conjoint therapy with glutaminase inhibitors. The invention relates to methods of treating cancer... |
|
|
G/S
|
House mark for pharmaceuticals for the treatment of cancer, tumors, oncological diseases and diso... |
|
|
G/S
|
House mark for pharmaceuticals for the treatment of cystic fibrosis; house mark for pharmaceutica... |
|
|
Invention
|
Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide. A method... |
|
|
Invention
|
Combination therapy with glutaminase inhibitors.
The invention relates to methods of treating ca... |
|
|
Invention
|
Combination therapy with glutaminase inhibitors. The invention relates to methods of treating can... |
|
2017
|
Invention
|
Compositions and methods for inhibiting arginase activity. The disclosure relates to a novel clas... |
|
|
Invention
|
Arginase inhibitor combination therapies. The disclosure relates to methods of treating or preven... |
|
|
Invention
|
Combination therapy with glutaminase inhibitors. The invention relates to novel heterocyclic comp... |
|
|
Invention
|
Treatment of cancer with inhibitors of glutaminase. The invention relates to method of treating a... |
|
2016
|
Invention
|
Compositions and methods for inhibiting arginase activity. The invention relates to a novel class... |
|
|
Invention
|
Combination pharmaceutical compositions and uses thereof. The present invention provides for meth... |
|
|
Invention
|
Treatment of lung cancer with inhibitors of glutaminase. The invention relates to methods of trea... |
|
|
Invention
|
Methods of administering glutaminase inhibitors.
In some aspects, the invention relates to a met... |
|
2015
|
Invention
|
Crystal forms of glutaminase inhibitors. The invention relates to crystalline salts of a heterocy... |
|
|
Invention
|
Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase. The invention relates ... |
|
|
G/S
|
Pharmaceuticals for the treatment of cancer; pharmaceutical preparations; drug delivery devices f... |
|
|
G/S
|
Research and development of pharmaceuticals for the treatment of cancer; research and development... |
